An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Status:
Recruiting
Trial end date:
2024-04-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether BMS-986288 both by itself and in
combination with Nivolumab is safe and tolerable in the treatment of select advanced solid
tumors.